Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)

Organon and Co496 enrolled

Overview

The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart. The results showed that after an average treatment time of 4.8 years, treatment that was based on losartan was better than treatment based on atenolol for reducing the risk of having a stroke. The main study results were published in Dahlof et al. Lancet 2002;359:995-1003.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

496

Conditions

Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)

Interventions

MK0954, /Duration of Treatment : 5 YearsDRUG

Comparator : atenolol /Duration of Treatment : 5 YearsDRUG

Eligibility

Sex: ALLMin age: 55 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 55 to 80 years * Males and females * Hypertension (160-200/95-115 mm Hg * ECG evidence of left ventricular hypertrophy Exclusion Criteria: * Need for treatment with angiotensin converting enzyme inhibitors, or open- label angiotensin receptor blockers or beta-blockers * Myocardial infarction or stroke within 6 months

Outcomes

Primary Outcomes

Composite of cardiovascular death, fatal and nonfatal stroke, fatal and nonfatal myocardial infarction (heart attack)

Secondary Outcomes

cardiovascular death, stroke, myocardial infarction, all-cause mortality, hospitalization for heart failure, new-onset diabetes mellitus

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.